Modelling Anxiety in Humans for Drug Development

Publisher： Bentham Science Publishers

E-ISSN： 1875-6190|5|1|65-72

ISSN： 1570-159X

Source： Current Neuropharmacology, Vol.5, Iss.1, 2007-03, pp. : 65-72

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Modelling during drug development

By Balant L.P.   Gex-Fabry M.  

European Journal of Pharmaceutics and Biopharmaceutics, Vol. 50, Iss. 1, 2000-07 ,pp. : 13-26

Elsevier

Access to resources Recommend Favorite

Modelling neurodegeneration in prion disease – applications for drug development

By Uppington Kay M   Brown David R  

Expert Opinion on Drug Discovery, Vol. 2, Iss. 6, 2007-06 ,pp. : 777-788

Informa Healthcare

Access to resources Recommend Favorite

Role of modelling and simulation in Phase I drug development

By Aarons L.   Karlsson M.O.   Mentre F.   Rombout F.   Steimer J.-L.   van Peer A.   invited COST B15 Experts  

European Journal of Pharmaceutical Sciences, Vol. 13, Iss. 2, 2001-05 ,pp. : 115-122

Elsevier

Access to resources Recommend Favorite

Modelling and simulation of placebo effect: application to drug development in schizophrenia

By Pilla Reddy Venkatesh  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 40, Iss. 3, 2013-06 ,pp. : 377-388

Springer Publishing Company

Access to resources Recommend Favorite

Hepatitis C Virus Proteins as Targets for Drug Development: The Role of Bioinformatics and Modelling

By  

Current Drug Targets, Vol. 3, Iss. 4, 2002-08 ,pp. : 281-296

Bentham Science Publishers

Access to resources Recommend Favorite